Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific reporting date of January 13, 2021. The document serves as a transaction notification regarding the acquisition of ordinary shares by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific share transactions.
| Transaction Date | Instrument | Price per Share | Total Volume per Executive | Exchange |
|---|---|---|---|---|
| 2021-01-12 | Ordinary Shares (25p each) | £13.8425 | 18 Shares (9 partnership + 9 matching) | London Stock Exchange (XLON) |
Note: The volume listed above applies individually to each of the 12 executives disclosed in the filing. The total aggregate volume for all transactions reported in this filing is 216 shares.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine regulatory disclosure of insider share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions are standard acquisitions under the Share Reward Plan, involving both partnership shares and matching shares.
Important Facts for Investors
- Transaction Nature: All reported transactions are acquisitions of ordinary shares by senior executives under the Share Reward Plan, indicating alignment with shareholder interests.
- Participants: The filing covers 12 individuals, including the CEO (Ms. E. Walmsley), President of Global Vaccines (Mr. R. Connor), and other SVPs and officers.
- Valuation: All shares were acquired at a uniform price of £13.8425 on January 12, 2021.
- Scope: This document is not a financial results report; investors should refer to Form 20-F or quarterly earnings releases for financial performance data.